HOPO Therapeutics is a privately-held, clinical-stage pharmaceutical company developing treatments for heavy metal poisoning and pioneering novel methods for directed radioisotope delivery. Leveraging world-class expertise in the chemistry and biochemistry of heavy metals and technology licensed from Lawrence Berkeley National Laboratory, HOPO’s mission is to safeguard all people throughout the world from the harmful effects of heavy metal contamination while utilizing the power of metals in medicine to cure disease and improve lives.
Company Details
- Employees
- 13
- Founded
- -
- Address
- San Francisco Bay Area, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.hopotx.com
- Keywords
- Women's and Children's Health, Global Environmental Health, Lead Poisoning, Heavy Metal Toxicity, Health Security, Oncology, Radioligand Therapy.
- HQ
- San Francisco Bay Area
Hopo Therapeutics Questions
Hopo Therapeutics's website is http://www.hopotx.com
Hopo Therapeutics's LinkedIn profile is https://www.linkedin.com/company/hopotx
Hopo Therapeutics has
13 employees.
View email and phone details for 13
employees at Hopo Therapeutics.
Hopo Therapeutics's industry is
Biotechnology Research
Hopo Therapeutics's top competitors are
Scribe Therapeutics,
Axent Biosciences,
Bakar Fellows Program,
Catenabio,
Umaro Foods,
Resvita Bio,
Elenae Therapeutics, Inc.,
Bakar Bio Labs,
Biomedical Advanced Research And Development Authority (Barda),
Oishii.
Hopo Therapeutics's categories are Biotechnology Research
Hopo Therapeutics's founding year is 2020
